Increased interleukin-6 and macrophage chemoattractant protein-1 are associated with respiratory failure in COVID-19

Author:

Jøntvedt Jørgensen MartheORCID,Holter Jan CatoORCID,Christensen Erik Egeland,Schjalm Camilla,Tonby Kristian,Pischke Søren Erik,Jenum Synne,Skeie Linda G.,Nur Sarah,Lind AndreasORCID,Opsand Hanne,Enersen Tone Burvald,Grøndahl Ragnhild,Hermann Anne,Dudman SusanneORCID,Muller Fredrik,Ueland Thor,Mollnes Tom Eirik,Aukrust Pål,Heggelund Lars,Holten Aleksander Rygh,Dyrhol-Riise Anne MaORCID

Abstract

AbstractIn SARS-CoV-2 infection there is an urgent need to identify patients that will progress to severe COVID-19 and may benefit from targeted treatment. In this study we analyzed plasma cytokines in COVID-19 patients and investigated their association with respiratory failure (RF) and treatment in Intensive Care Unit (ICU). Hospitalized patients (n = 34) with confirmed COVID-19 were recruited into a prospective cohort study. Clinical data and blood samples were collected at inclusion and after 2–5 and 7–10 days. RF was defined as PaO2/FiO2 ratio (P/F) < 40 kPa. Plasma cytokines were analyzed by a Human Cytokine 27-plex assay. COVID-19 patients with RF and/or treated in ICU showed overall increased systemic cytokine levels. Plasma IL-6, IL-8, G-CSF, MCP-1, MIP-1α levels were negatively correlated with P/F, whereas combinations of IL-6, IP-10, IL-1ra and MCP-1 showed the best association with RF in ROC analysis (AUC 0.79–0.80, p < 0.05). During hospitalization the decline was most significant for IP-10 (p < 0.001). Elevated levels of pro-inflammatory cytokines were present in patients with severe COVID-19. IL-6 and MCP-1 were inversely correlated with P/F with the largest AUC in ROC analyses and should be further explored as biomarkers to identify patients at risk for severe RF and as targets for improved treatment strategies.

Funder

Norges Forskningsråd

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Reference57 articles.

1. Medicine, J. H. U. o. Coronavirus Resource Center. https://coronavirus.jhu.edu/map.html (2020).

2. Organization, W. H. Novel Coronavirus (2019-nCoV) Situation Report-1. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf (2020).

3. Organization, W. H. Coronavirus Disease (COVID-19)—Situation Report 115. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200514-covid-19-sitrep-115.pdf?sfvrsn=3fce8d3c_6 (2020).

4. Organization, W. H. Coronavirus Disease (COVID-19) Outbreak—WHO Announces COVID-19 Outbreak a Pandemic. http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/3/who-announces-covid-19-outbreak-a-pandemic (2020).

5. Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727–733. https://doi.org/10.1056/NEJMoa2001017 (2020).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3